Z-YVAD-FMK

Cell lines

Caco-2 (ATCC Number HTB-37)

Preparation method

Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reaction Conditions

48 h

Applications

Z-YVAD-FMK significantly downregulates the growth inhibition induced by butyrate in Caco-2 Cells. Complete abrogation of butyrate’s effect occurs at an inhibitor concentration of 100 μmol/L, indicating that caspase-1 inhibitor significantly alters the caspase cascade, diminishing the butyrate-induced apoptotic effect.

Animal models

Albino Wistar rats

Dosage form

Rats were injected intravenously (2 μL) with caspase inhibitor Z-VAD-FMK (1.06 mM in 2% DMSO)

Applications

Immediately before exposure to damaging light, YVAD significantly reduces caspase-1 activity to 51% ± 34% but has no effect on caspase-3 activity (98% ± 5%). Exposed-YVAD retinas showed caspase-1 activities of 66% ± 33%, respectively. These values were significantly (P < 0.02 and P < 0.004, respectively) lower than in the Exposed-DMSO group.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Avivi-Green C, Polak-Charcon S, Madar Z, Schwartz B. Different molecular events account for butyrate-induced apoptosis in two human colon cancer cell lines. J Nutr. 2002 Jul;132(7):1812-8.

2. Perche O, Doly M, Ranchon-Cole I. Caspase-dependent apoptosis in light-induced retinal degeneration. Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2753-9.